Interleukin-10

Anti Inflammatory CytokineRx: ResearchCompound: Investigational

Also known as: CSIF (Cytokine Synthesis Inhibitory Factor), IL-10, Ilodecakin, Interleukin 10, Pegilodecakin, rIL-10, Tenovil

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Interleukin-10 at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Interleukin‑10 (IL‑10) is an anti‑inflammatory cytokine studied for its immunomodulatory properties. Research explores its role in metabolic disorders, muscle wasting, allergic disease, and mental health, often as a biomarker or genetic factor rather than a therapeutic agent. Current evidence is confined to observational studies, meta‑analyses of polymorphisms, and mechanistic investigations in humans and animal models.

Mechanism of Action

IL‑10 binds to the heterodimeric IL‑10 receptor (IL‑10R1/IL‑10R2) on immune cells, triggering JAK1 and TYK2 activation and subsequent STAT3 phosphorylation. Activated STAT3 translocates to the nucleus, driving transcription of genes that suppress pro‑inflammatory cytokines (e.g., IFN‑γ, TNF‑α) and inhibit antigen‑presenting cell maturation. In innate lymphoid cells, IL‑10 production limits Th2 responses and preserves epithelial integrity, contributing to tolerance during allergen immunotherapy.

What the Research Shows

Meta‑analyses of serum IL‑10 levels show no significant link with gestational diabetes risk or with changes after resistance training in sarcopenic Asian adults. Genetic studies reveal that certain IL‑10 promoter SNPs (rs1800896, rs1800871) are associated with reduced asthma susceptibility in specific ethnic groups, while other polymorphisms do not affect leishmaniasis progression. A probiotic trial reported increased circulating IL‑10 alongside reduced stress and anxiety markers. Immunotherapy research identified IL‑10‑producing type 2 innate lymphoid cells as mediators of clinical response in grass‑pollen allergy. Overall, IL‑10 is implicated in immune regulation, but direct therapeutic trials are scarce.

Reported Benefits

Evidence suggests IL‑10 may contribute to immune tolerance, as seen in allergen immunotherapy where IL‑10‑producing ILC2s correlate with symptom improvement. Certain IL‑10 gene variants appear protective against asthma, indicating a potential genetic advantage. In a probiotic study, elevated IL‑10 accompanied reductions in stress‑related hormones and inflammatory markers, hinting at a role in mental‑health modulation.

Limitations of the Evidence

Most data are observational or derived from meta‑analyses of polymorphisms, limiting causal inference. Serum IL‑10 levels did not differ in gestational diabetes or after resistance training, and no association was found with leishmaniasis progression. Protective SNP effects are population‑specific and not universally reproducible. Direct interventional studies administering IL‑10 are lacking, so therapeutic benefits remain unproven.

Safety Considerations

The abstracts provide no information on adverse events from recombinant IL‑10 administration. As an investigational protein, its safety profile in humans is not established in the cited literature. Potential immunosuppressive effects, such as impaired pathogen clearance, are theoretical concerns based on its biological activity, underscoring the need for formal safety evaluations before clinical use.

How It Is Administered

In research settings, IL‑10 has been delivered intravenously or subcutaneously as a recombinant protein. Formulations are typically sterile solutions prepared for parenteral injection. No dosing regimens or approved therapeutic formulations are described in the cited studies; administration is confined to experimental protocols.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • PsoriasisDermatology / InflammatoryModerate
  • Inflammatory bowel disease / Crohn's diseaseAutoimmune / InflammatoryModerate
  • autoimmune disease controlAutoimmunityLow
  • anti‑inflammatory therapyImmunomodulationModerate
  • Rheumatoid arthritisAutoimmune DiseaseLow
  • Sepsis / systemic inflammationCritical CareLow
  • Cancer immunotherapyOncologyModerate

Contraindications

  • known hypersensitivity to IL‑10 or formulation componentsAllergyHigh
  • Severe immunodeficiencyImmunologyHigh
  • Active severe infectionInfectiousModerate
  • Hypersensitivity to IL-10 or recombinant human proteinsAllergy / ImmunologyHigh
  • Active severe infectionsInfectious DiseaseHigh

Adverse Effects

  • hematologic abnormalities (anemia, thrombocytopenia)HematologicUncommon
  • Injection site reactionsLocalCommon
  • Anemia / thrombocytopeniaHematologicCommon
  • Flu-like symptoms (fever, chills, myalgia)SystemicCommon
  • Flu‑like syndromeSystemicCommon
  • Autoantibody inductionImmunologicUncommon
  • Opportunistic infectionsInfectiousUncommon
  • Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
  • Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

  • Live vaccinesHigh
  • Biologics / TNF inhibitorsModerate
  • Chemotherapeutic agentsLow
  • CorticosteroidsModerate
  • Immunosuppressants (e.g., cyclosporine, methotrexate)Moderate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Patients with active malignancyOncologyRelative
  • Pediatric populationsAgeRelative
  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative

Regulatory Status

  • European UnionInvestigationalClinical studies ongoing; not authorized for marketing
  • United StatesInvestigationalPhase I/II trials for solid tumors and inflammatory disorders
  • United KingdomUnknownNo approved indication; research use only.

Recombinant human IL-10 (ilodecakin) was investigated by Schering-Plough but not approved by FDA or EMA for any indication. Pegilodecakin (AM0010) received FDA Fast Track designation for certain cancers but failed Phase III trials. No approved therapeutic formulation exists as of 2024.

Evidence & Sources

Frequently Asked Questions

What is the primary biological role of interleukin‑10?

IL‑10 is a key anti‑inflammatory cytokine that binds its receptor to activate JAK‑STAT3 signaling, suppressing pro‑inflammatory cytokine production and dampening immune activation, thereby promoting tolerance and limiting tissue damage.

Has IL‑10 been shown to prevent gestational diabetes?

A meta‑analysis of ten studies found no significant difference in serum IL‑10 levels between women with gestational diabetes and healthy controls, indicating no clear protective effect.

Do IL‑10 gene variants affect asthma risk?

Yes, certain promoter polymorphisms (e.g., rs1800896, rs1800871) are associated with a decreased risk of asthma in European and African populations, though results vary by ethnicity and study design.

Can IL‑10 be used as a treatment for stress or anxiety?

Human probiotic research showed that increased IL‑10 levels coincided with reduced stress markers, but IL‑10 itself was not administered; thus, its direct therapeutic role for mental health remains untested.

What is Interleukin-10 used for?

Interleukin-10 is educationally associated with: Psoriasis, Inflammatory bowel disease / Crohn's disease, autoimmune disease control, anti‑inflammatory therapy, Rheumatoid arthritis, Sepsis / systemic inflammation, Cancer immunotherapy. Educational only — not medical advice.

How is Interleukin-10 administered?

Recorded routes of administration: Intravenous, Subcutaneous.

What are the potential side effects of Interleukin-10?

Reported adverse effects include: hematologic abnormalities (anemia, thrombocytopenia), Injection site reactions, Anemia / thrombocytopenia, Flu-like symptoms (fever, chills, myalgia), Flu‑like syndrome, Autoantibody induction, Opportunistic infections, Injection site reaction, Elevated liver enzymes. This list is not exhaustive — consult a qualified clinician.

Who should avoid Interleukin-10?

Recorded contraindications: known hypersensitivity to IL‑10 or formulation components, Severe immunodeficiency, Active severe infection, Hypersensitivity to IL-10 or recombinant human proteins, Active severe infections. Consult a qualified clinician before use.

More Cytokines and Chemokines

See all Cytokines and Chemokines →

Browse All PeptidesBuild My Stack